Decreased central opioid activity in premenstrual syndrome

Luteinizing hormone response to naloxone

Andrea J. Rapkin, Donna Shoupe, Anthony Reading, K. Kevin Daneshgar, Linda Goldman, Yvonne Bohn, Darrell W Brann, Virenda B. Mahesh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To evaluate central opioid activity in women with prospectively documented premenstrual syndrome (PMS) and control women in the mid- and late luteal phases of the menstrual cycle. Methods: Blood was collected every 15 minutes 1 hours before (0800) and 2 hours after treatment (0900-1100). The treatment was administered in a randomized fashion and consisted of naloxone 1 or 4 mg or placebo, and blood was assayed for luteinizing hormone (LH). Baseline estradiol, progesterone, and prolactin were measured at 0800 and 0900 hours. Results: There was a significant increase in LH area under the curve and mean LH in response to naloxone in the midluteal phase in the controls (P < .001). The PMS subjects did not display a significant increase in LH concentration in response to naloxone in the midluteal phase. There were no significant LH responses to naloxone in either group in the late luteal phase. There were no significant differences in estradiol, progesterone, or prolactin concentrations or estrogen to progesterone ratios between groups. Conclusion: Control women have an enhanced central opioid tone during the midluteal phase that diminishes and becomes minimal in the late luteal phase of the menstrual cycle. In contrast, women with PMS have a loss of central opioid tone during the midluteal phase as indicated by the loss of LH response to naloxone. This attenuated central opioid tone in women with PMS as compared with asymptomatic control women may play a role in the pathophysiology of PMS.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalJournal of the Society for Gynecologic Investigation
Volume3
Issue number2
DOIs
StatePublished - Mar 1 1996
Externally publishedYes

Fingerprint

Premenstrual Syndrome
Naloxone
Luteinizing Hormone
Opioid Analgesics
Luteal Phase
Progesterone
Prolactin
Estradiol
Area Under Curve
Estrogens
Placebos
Therapeutics

Keywords

  • LH response to naloxone
  • PMS
  • central opioid activity

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Decreased central opioid activity in premenstrual syndrome : Luteinizing hormone response to naloxone. / Rapkin, Andrea J.; Shoupe, Donna; Reading, Anthony; Daneshgar, K. Kevin; Goldman, Linda; Bohn, Yvonne; Brann, Darrell W; Mahesh, Virenda B.

In: Journal of the Society for Gynecologic Investigation, Vol. 3, No. 2, 01.03.1996, p. 93-98.

Research output: Contribution to journalArticle

Rapkin, Andrea J. ; Shoupe, Donna ; Reading, Anthony ; Daneshgar, K. Kevin ; Goldman, Linda ; Bohn, Yvonne ; Brann, Darrell W ; Mahesh, Virenda B. / Decreased central opioid activity in premenstrual syndrome : Luteinizing hormone response to naloxone. In: Journal of the Society for Gynecologic Investigation. 1996 ; Vol. 3, No. 2. pp. 93-98.
@article{8fb4c1c925a0400dac10f9e6b8b87212,
title = "Decreased central opioid activity in premenstrual syndrome: Luteinizing hormone response to naloxone",
abstract = "Objective: To evaluate central opioid activity in women with prospectively documented premenstrual syndrome (PMS) and control women in the mid- and late luteal phases of the menstrual cycle. Methods: Blood was collected every 15 minutes 1 hours before (0800) and 2 hours after treatment (0900-1100). The treatment was administered in a randomized fashion and consisted of naloxone 1 or 4 mg or placebo, and blood was assayed for luteinizing hormone (LH). Baseline estradiol, progesterone, and prolactin were measured at 0800 and 0900 hours. Results: There was a significant increase in LH area under the curve and mean LH in response to naloxone in the midluteal phase in the controls (P < .001). The PMS subjects did not display a significant increase in LH concentration in response to naloxone in the midluteal phase. There were no significant LH responses to naloxone in either group in the late luteal phase. There were no significant differences in estradiol, progesterone, or prolactin concentrations or estrogen to progesterone ratios between groups. Conclusion: Control women have an enhanced central opioid tone during the midluteal phase that diminishes and becomes minimal in the late luteal phase of the menstrual cycle. In contrast, women with PMS have a loss of central opioid tone during the midluteal phase as indicated by the loss of LH response to naloxone. This attenuated central opioid tone in women with PMS as compared with asymptomatic control women may play a role in the pathophysiology of PMS.",
keywords = "LH response to naloxone, PMS, central opioid activity",
author = "Rapkin, {Andrea J.} and Donna Shoupe and Anthony Reading and Daneshgar, {K. Kevin} and Linda Goldman and Yvonne Bohn and Brann, {Darrell W} and Mahesh, {Virenda B.}",
year = "1996",
month = "3",
day = "1",
doi = "10.1016/1071-5576(95)00045-3",
language = "English (US)",
volume = "3",
pages = "93--98",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Decreased central opioid activity in premenstrual syndrome

T2 - Luteinizing hormone response to naloxone

AU - Rapkin, Andrea J.

AU - Shoupe, Donna

AU - Reading, Anthony

AU - Daneshgar, K. Kevin

AU - Goldman, Linda

AU - Bohn, Yvonne

AU - Brann, Darrell W

AU - Mahesh, Virenda B.

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Objective: To evaluate central opioid activity in women with prospectively documented premenstrual syndrome (PMS) and control women in the mid- and late luteal phases of the menstrual cycle. Methods: Blood was collected every 15 minutes 1 hours before (0800) and 2 hours after treatment (0900-1100). The treatment was administered in a randomized fashion and consisted of naloxone 1 or 4 mg or placebo, and blood was assayed for luteinizing hormone (LH). Baseline estradiol, progesterone, and prolactin were measured at 0800 and 0900 hours. Results: There was a significant increase in LH area under the curve and mean LH in response to naloxone in the midluteal phase in the controls (P < .001). The PMS subjects did not display a significant increase in LH concentration in response to naloxone in the midluteal phase. There were no significant LH responses to naloxone in either group in the late luteal phase. There were no significant differences in estradiol, progesterone, or prolactin concentrations or estrogen to progesterone ratios between groups. Conclusion: Control women have an enhanced central opioid tone during the midluteal phase that diminishes and becomes minimal in the late luteal phase of the menstrual cycle. In contrast, women with PMS have a loss of central opioid tone during the midluteal phase as indicated by the loss of LH response to naloxone. This attenuated central opioid tone in women with PMS as compared with asymptomatic control women may play a role in the pathophysiology of PMS.

AB - Objective: To evaluate central opioid activity in women with prospectively documented premenstrual syndrome (PMS) and control women in the mid- and late luteal phases of the menstrual cycle. Methods: Blood was collected every 15 minutes 1 hours before (0800) and 2 hours after treatment (0900-1100). The treatment was administered in a randomized fashion and consisted of naloxone 1 or 4 mg or placebo, and blood was assayed for luteinizing hormone (LH). Baseline estradiol, progesterone, and prolactin were measured at 0800 and 0900 hours. Results: There was a significant increase in LH area under the curve and mean LH in response to naloxone in the midluteal phase in the controls (P < .001). The PMS subjects did not display a significant increase in LH concentration in response to naloxone in the midluteal phase. There were no significant LH responses to naloxone in either group in the late luteal phase. There were no significant differences in estradiol, progesterone, or prolactin concentrations or estrogen to progesterone ratios between groups. Conclusion: Control women have an enhanced central opioid tone during the midluteal phase that diminishes and becomes minimal in the late luteal phase of the menstrual cycle. In contrast, women with PMS have a loss of central opioid tone during the midluteal phase as indicated by the loss of LH response to naloxone. This attenuated central opioid tone in women with PMS as compared with asymptomatic control women may play a role in the pathophysiology of PMS.

KW - LH response to naloxone

KW - PMS

KW - central opioid activity

UR - http://www.scopus.com/inward/record.url?scp=0030060031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030060031&partnerID=8YFLogxK

U2 - 10.1016/1071-5576(95)00045-3

DO - 10.1016/1071-5576(95)00045-3

M3 - Article

VL - 3

SP - 93

EP - 98

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 2

ER -